Premium
Interleukin‐3. Biologic effects and clinical impact
Author(s) -
Oster Wolfgang,
Frisch Jürgen,
Nicolay Uwe,
Schulz Gregor
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910515)67:10+<2712::aid-cncr2820671708>3.0.co;2-o
Subject(s) - medicine , granulocyte macrophage colony stimulating factor , haematopoiesis , eosinophil , immunology , interleukin 3 , clinical trial , interleukin , colony stimulating factor , granulocyte , cancer research , cytokine , t cell , biology , microbiology and biotechnology , stem cell , il 2 receptor , immune system , asthma
Human interleukin‐3 (IL‐3) is expressed in yeast and has a specific activity of 5 × 10 7 U/mg of protein. It exerts functional and proliferative effects on multiple hematopoietic cell lineages including the neutrophil, eosinophil, basophil, monocytic, and thrombopoietic cell lines. IL‐3 and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) share common binding capacities on hematopoietic cells. Each of these agents has entered clinical trials. The clinical experiences with IL‐3 alone and in combination with GM‐CSF in a Phase I/II trial are summarized in this report.